New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

346 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-18

Study Completion Date

2020-06-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the efficacy of three experimental antibiotics in the treatment of uncomplicated anogenital gonorrhoea. Participants will be randomized to one of four study arms and will receive either one of the three experimental antibiotics (ertapenem, fosfomycin and gentamicin) or the current standard antibiotic (ceftriaxone). Both the study team and the participant are blinded to the administered treatment. This enables the investigators to compare the eradication capacity and safety of the experimental antibiotics with the standard treatment.

\*Following the advise of the DSMB based on a planned interim analysis, in October 2018 one study arm (fosfomycin 6g PO) was dropped and the randomized clinical trial was continued with three treatment arms (ceftriaxone 500mg IM, ertapenem 1000mg IM and gentamicin 5mg/kg IM) and without the oral placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections

NCT07063095

Gram Negative Infections Sepsis and Septic Shock

RECRUITING PHASE3

Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

NCT06080698

Gram-negative Bacteremia

RECRUITING NA

A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.

NCT06806995

PHA1A

COMPLETED PHASE1

Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue

NCT04484740

Gonorrhea Infection, Bacterial

COMPLETED PHASE1

Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.

NCT03228108

Complication Infection Prostate Cancer

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Antimicrobial resistance (AMR) to extended spectrum cephalosporins (ESC) among Neisseria gonorrhoeae (Ng) is a major public health concern. With no alternative antimicrobial treatment options for gonorrhoea and only a few new drugs in the development pipeline, it is important to test existing antibiotics for their efficacy in gonorrhoea treatment. This project aims to identify new treatment modalities for uncomplicated gonorrhoea using the registered drugs ertapenem, fosfomycin and gentamicin. This trial is a double blind randomized clinical non-inferiority trial with four treatment arms. 108 participants are randomly assigned to each study arm . Participants will receive either ceftriaxone 500mg intramuscularly (IM) or ertapenem 1000mg IM or gentamicin 5mg/kg IM with a maximum of 400mg (in two doses) supplemented with an oral placebo, or receive fosfomycin 6g oral suspension supplemented with an intramuscular placebo. The bacterial eradication capacity of the study antimicrobials at the included infection site is measured 7-14 days after treatment, using an RNA-based Nucleic Acid Amplification Test (NAAT).

\*Following the advise of the DSMB based on a planned interim analysis, in October 2018 one study arm (fosfomycin 6g PO) was dropped and the randomized clinical trial was continued with three treatment arms (ceftriaxone 500mg IM, ertapenem 1000mg IM and gentamicin 5mg/kg IM) and without the oral placebo.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gonorrhea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A double-blind randomized clinical trial with non-inferiority design

\*since October 2018 one study arm (fosfomycin) has been dropped. In a subset of these participants the plasma concentration of ceftriaxone, ertapenem and gentamicin is measured.

An open-label randomized substudy evaluating the pharmacokinetics of ceftriaxone ertapenem and fosfomycin in 60 healthy volunteers (this number is in addition to the 346 NABOGO participants with gonorrhea)

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

All participants receive either intramuscular treatment and if applicable intramuscular placebo. Both particpant and care provider are blind to the regimen.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ceftriaxone im

Current standard treatment. Ceftriaxone 500mg (single intramuscular dose) + placebo (single oral dose)

Group Type ACTIVE_COMPARATOR

Ceftriaxone

Intervention Type DRUG

single dose 500mg intramuscular injection

Ertapenem im

Ertapenem 1000mg (single intramuscular dose) + placebo (single oral dose)

Group Type EXPERIMENTAL

Ertapenem 1000 MG

Intervention Type DRUG

single dose 1000mg intramuscular injection

Fosfomycin po

Fosfomycin oral suspension 6g (single oral dose) + placebo (single intramuscular dose)

Group Type EXPERIMENTAL

Fosfomycin Oral Suspension

Intervention Type DRUG

single dose 6g oral suspension

Gentamicin im

Gentamicin sulfate, injectable 5mg/kg (single intramuscular dose) + placebo (single oral dose)

Group Type EXPERIMENTAL

Gentamicin Sulfate, Injectable

Intervention Type DRUG

single dose 5mg/kg (maximum 400mg) intramuscular injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ertapenem 1000 MG

single dose 1000mg intramuscular injection

Intervention Type DRUG

Fosfomycin Oral Suspension

single dose 6g oral suspension

Intervention Type DRUG

Gentamicin Sulfate, Injectable

single dose 5mg/kg (maximum 400mg) intramuscular injection

Intervention Type DRUG

Ceftriaxone

single dose 500mg intramuscular injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Invanz Monuril no other names no other names

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years or older
* Anorectal, cervical/vaginal or urethral Ng infection, diagnosed by the following:

* Ng-positive Gram-stained smear (intracellular Gram-negative diplococci and leukocytes) and/or
* Positive for Ng by nucleic acid amplification test (NAAT) (Aptima Combo 2) and/or
* Positive for Ng by culture
* Provide samples from the included infection site for NAAT and direct culture immediately before treatment
* Willing to abstain from anal, vaginal and oral sex until the test of cure (TOC)-visit, or use condoms during sex
* Willing and able to return for a TOC-visit 7-14 days after treatment
* Provide informed consent
* Accept intramuscular injections

* 18 years or older
* Provide informed consent

Exclusion Criteria

Pre-randomisation:

* Suspicion of a complicated Ng infection based on signs and/or symptoms indicating pelvic inflammatory disease (PID), epididymitis, prostatitis or gonococcal arthritis\*
* Another (sexually transmitted) infection or a suspicion of another infection for which systemic antimicrobial therapy is indicated
* Pregnancy, having a wish to become pregnant or breastfeeding (tested at inclusion visit)
* Not able to read/understand Dutch or English
* HIV infection if:

* Newly diagnosed HIV infection (upon the inclusion visit) and/or
* CD4+ cell-count \<200 cells/μL (as reported by the patient)
* Known allergy or adverse reactions to ceftriaxone, ertapenemor gentamicin
* Known renal impairment (based on estimated GFR using Cockroft and Gault formula using serum creatinin measured with a point-of-care (POC) test; cut off value renal impairment eGFR ≤ 50 ml/min)
* Known liver cirrhosis (based on history)
* Known congestive heart failure (based on history)
* Known myasthenia gravis
* Known hearing loss or balance disorder, confirmed by an ear-nose-throat (ENT)-doctor or for which an ENT doctor has been consulted and a diagnostic process is still in progress (based on history)
* Concurrent use of any of the following medication:

* systemic antibacterial antimicrobials other than nitrofurantoin or metronidazole
* systemic immunosuppressive drugs
* systemic valproic acid
* Use of any antimicrobial therapy other than nitrofurantoin or metronidazole in the two weeks prior to study enrollment (based on history)
* Previous enrollment in the study
* Concurrent participation in other non-observational medical research\*
* Unlikely to adhere to the study protocol

Post-randomisation:

Exclusion of participants from the modified intention to treat analysis (mITT):

* Negative result of Ng NAAT of sample collected on T0 (the day of treatment). This could be the case in the following situations:

1. Negative NAAT in spite of positive gram stain.
2. Positive NAAT on pre-study visit but spontaneous clearance of the infection in the time period between first test and return visit for treatment (=study inclusion visit). A novel sample for NAAT will be collected on the study inclusion visit just before administration of treatment; if these results are Ng-negative a participant will be excluded of mITT.
* Loss to follow-up, i.e. no study visit TOC 7-14 days after treatment administration.

Exclusion from per protocol analysis (PP):

* Exclusion of mITT
* Use of non-study related antibiotics after inclusion and prior to TOC visit
* Condomless sexual contact with the primary anatomical gonorrhea site involved after inclusion and prior to TOC visit
* Other protocol violations

Pre-randomisation:

* Pregnancy, having a wish to become pregnant or breastfeeding (tested at inclusion visit)
* Not able to read/understand Dutch or English
* Known allergy or adverse reactions to ceftriaxone, ertapenem, or fosfomycin.
* Known renal impairment (based on estimated GFR using Cockroft and Gault formula using serum creatinin measured with a point-of-care (POC) test; cut off value renal impairment eGFR ≤ 50 ml/min)
* Known liver cirrhosis (based on history)
* Concurrent use of any of the following medication:

* systemic valproic acid
* systemic metoclopramide
* Use of any systemic antimicrobial therapy other than nitrofurantoin or metronidazole in the two weeks prior to study enrollment (based on history)
* Concurrent participation in other non-observational medical research (apart from NABOGO RCT)
* Unlikely to adhere to the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes